Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

Pfizer abandoned the development of danuglipron and plans to focus its efforts on GIPR candidates and other earlier obesity programs.

BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Morgan Stanley analyst Terence Flynn notes that Pfizer (PFE) announced that after a review of the totality of the data for its pipeline oral ...

Pfizer on Monday said it had discontinued the development of the experimental weight-loss pill danuglipron after a trial ...

The Dow Jones Industrial Average added 312.08 points, or 0.78%, to close at 40,524.79. The Nasdaq Composite rose 0.64% to end ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Consumers may cycle on and off GLP-1 medications because of financial constraints. These consumers present opportunities for ...